CO2019013554A2 - Composiciones de fármaco mejoradas de liberación extendida y altamente cargadas - Google Patents

Composiciones de fármaco mejoradas de liberación extendida y altamente cargadas

Info

Publication number
CO2019013554A2
CO2019013554A2 CONC2019/0013554A CO2019013554A CO2019013554A2 CO 2019013554 A2 CO2019013554 A2 CO 2019013554A2 CO 2019013554 A CO2019013554 A CO 2019013554A CO 2019013554 A2 CO2019013554 A2 CO 2019013554A2
Authority
CO
Colombia
Prior art keywords
drug
component
carbomer
extended release
drug compositions
Prior art date
Application number
CONC2019/0013554A
Other languages
English (en)
Inventor
Liliana A Miinea
Elena S Draganoiu
Kedar V Chikhalikar
Vikrant V Chadawar
Original Assignee
Lubrizol Advanced Mat Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62200552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019013554(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lubrizol Advanced Mat Inc filed Critical Lubrizol Advanced Mat Inc
Publication of CO2019013554A2 publication Critical patent/CO2019013554A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La tecnología divulgada proporciona composiciones de fármaco mejoradas que proporcionan una mayor estabilidad, un mayor potencial de carga de fármaco y propiedades de disolución de fármaco adecuadas, y métodos para prepararlas. La composición incluye: (a) un componente de fármaco que comprende una cantidad terapéuticamente eficaz de un fármaco; (b) un componente de liberación prolongada que comprende un polímero de ácido poliacrílico reticulado que es un homopolímero de carbómero, copolímero de carbómero, interpolímero de carbómero, policarbofilo o una mezcla de estos; y (c) un componente amortiguador que comprende un agente amortiguador que contiene magnesio; en donde el componente de fármaco constituye al menos 50% en peso de la composición.
CONC2019/0013554A 2017-05-02 2019-11-29 Composiciones de fármaco mejoradas de liberación extendida y altamente cargadas CO2019013554A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762500078P 2017-05-02 2017-05-02
PCT/US2018/030380 WO2018204317A1 (en) 2017-05-02 2018-05-01 Improved extended release highly loaded drug compositions

Publications (1)

Publication Number Publication Date
CO2019013554A2 true CO2019013554A2 (es) 2020-04-01

Family

ID=62200552

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0013554A CO2019013554A2 (es) 2017-05-02 2019-11-29 Composiciones de fármaco mejoradas de liberación extendida y altamente cargadas

Country Status (12)

Country Link
US (2) US20200113839A1 (es)
EP (1) EP3618813B1 (es)
JP (1) JP7132947B2 (es)
KR (1) KR20190139942A (es)
CN (1) CN110709068B (es)
BR (1) BR112019022896A2 (es)
CA (1) CA3062158A1 (es)
CO (1) CO2019013554A2 (es)
ES (1) ES2924236T3 (es)
IL (1) IL270273B2 (es)
PE (1) PE20191795A1 (es)
WO (1) WO2018204317A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109839460A (zh) * 2019-03-14 2019-06-04 上海海虹实业(集团)巢湖今辰药业有限公司 一种阿莫西林有关物质的检测方法
CN110824066B (zh) * 2019-12-09 2022-05-20 北京悦康科创医药科技股份有限公司 一种头孢噻肟钠有关物质的检测方法
JP7300725B2 (ja) * 2020-02-27 2023-06-30 日新製薬株式会社 固形製剤及びその製造方法
CN112986435B (zh) * 2021-02-23 2022-08-05 海南通用三洋药业有限公司 一种注射用氨苄西林钠舒巴坦钠有关物质的测定方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
GB831897A (en) * 1957-07-08 1960-04-06 Bristol Myers Co Antacid preparation and process for making same
CH606154A5 (es) 1974-07-02 1978-11-15 Goodrich Co B F
US4267103A (en) 1978-12-07 1981-05-12 The B. F. Goodrich Company Solvent polymerization of carboxyl containing monomers
US4664915A (en) * 1981-07-01 1987-05-12 Bristol-Myers Company Compressed and formed alkaline component suitable for use in buffered aspirin product
US5288814A (en) 1992-08-26 1994-02-22 The B. F. Goodrich Company Easy to disperse polycarboxylic acid thickeners
US20040081697A1 (en) 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
JP4454985B2 (ja) 2002-08-08 2010-04-21 第一三共株式会社 血液脂質を低下させるための医薬組成物
EP1589957A1 (en) * 2003-02-05 2005-11-02 IPCA Laboratories Limited Pharmaceutical compositions and process of production thereof
CA2569968C (en) 2004-06-10 2014-08-19 Glatt Air Techniques, Inc. Controlled release matrix pharmaceutical dosage formulation
FR2879930B1 (fr) 2004-12-23 2007-08-31 Oralance Pharma Sa Nouveau systeme galenique pour le transport d'actif, procede de preparation et utilisation
WO2006082523A2 (en) * 2005-01-25 2006-08-10 Aurobindo Pharma Limited Pharmaceutical sustained release composition of metformin
NZ556630A (en) * 2005-01-27 2010-12-24 Alembic Ltd Extended release formulation of levetiracetam including a hydrophilic rate controlling polymer
CA2613631A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
JP2009500317A (ja) 2005-06-29 2009-01-08 パナセア バイオテック リミテッド 放出特性改良医薬組成物およびその製造方法
CA2653011A1 (en) * 2008-12-03 2010-06-03 Apotex Technologies Inc Method and apparatus for packaging and dispensing pharmaceuticals
MX370429B (es) * 2009-10-02 2019-12-13 Boehringer Ingelheim Int Gmbh Star Composiciones farmacéuticas que comprenden bi-1356 y metformina.
TWI636783B (zh) 2012-04-18 2018-10-01 友霖生技醫藥股份有限公司 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物
WO2015110962A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and linagliptin or salts thereof

Also Published As

Publication number Publication date
CN110709068A (zh) 2020-01-17
US20200113839A1 (en) 2020-04-16
JP2020518614A (ja) 2020-06-25
KR20190139942A (ko) 2019-12-18
EP3618813A1 (en) 2020-03-11
CN110709068B (zh) 2022-11-08
IL270273A (es) 2019-12-31
ES2924236T3 (es) 2022-10-05
BR112019022896A2 (pt) 2020-05-19
IL270273B2 (en) 2023-07-01
CA3062158A1 (en) 2018-11-08
IL270273B1 (en) 2023-03-01
EP3618813B1 (en) 2022-07-06
PE20191795A1 (es) 2019-12-24
WO2018204317A1 (en) 2018-11-08
JP7132947B2 (ja) 2022-09-07
US20220016035A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
CO2019013554A2 (es) Composiciones de fármaco mejoradas de liberación extendida y altamente cargadas
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
DOP2017000294A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
BR112016017352A2 (pt) copolímeros termoassociativos e permutáveis, composições que os compreendem
NZ723860A (en) Pharmaceutical compositions of therapeutically active compounds and their uses
ECSP17085669A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
EA201291372A1 (ru) Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
BR112019003945A2 (pt) composições oftálmicas
PH12017501933A1 (en) Bromodomain inhibitor
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
EA201992328A1 (ru) Фармацевтическая композиция, содержащая ленватиниба мезилат
SA518400220B1 (ar) تركيبة بوليمر تشتمل على بولي (ميثيل ميثاكريلات) وتركيبة معدلة التأثير
BR112021016603A2 (pt) Composição, e, processo
MX2020007293A (es) Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.
CL2017003350A1 (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc
MX2019014666A (es) Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo.
BR112017000462A2 (pt) detergente para lavar louça de pastilha e métodos para a fabricação e uso do mesmo
BR112019001544A2 (pt) composições poliméricas expansíveis em bloco
ECSP22054240A (es) Compuesto y composici?n como inhibidor de quinasa del receptor pdgf
PH12018500132A1 (en) Solid pharmaceutical compositions for treating hcv
WO2018220444A3 (en) COMPOSITIONS AND METHODS FOR TREATING DRY KERNATOCONJUNCTIVITIS SYNDROME BY ADMINISTERING A MACROLIDE ANTIBIOTIC
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
BR112014005535A2 (pt) composição, composição reticulada e artigo
AR117680A1 (es) Núcleo susceptible de recubrimiento para una formulación de un fármaco de liberación modificada
TR201922606A2 (tr) Ti̇zani̇di̇ni̇n bukkal fi̇lm formülasyonlari